Goldman Sachs Maintains Neutral on TG Therapeutics, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has maintained a Neutral rating on TG Therapeutics (NASDAQ:TGTX) and lowered the price target from $16 to $12.
August 04, 2023 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on TG Therapeutics and lowered the price target from $16 to $12.
The lowering of the price target by Goldman Sachs from $16 to $12 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on TG Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100